Effect of Tafamidis on Serum Transthyretin Levels in Non-Trial Patients With Transthyretin Amyloid Cardiomyopathy

BACKGROUND: Transthyretin amyloid (ATTR) cardiomyopathy is slowed by tafamidis, which stabilizes the TTR molecule and reduces the formation of amyloidogenic oligomers. Stabilizers in clinical doses raise serum TTR, which may be a surrogate for the degree of stabilization. OBJECTIVES: This study aims...

Descripción completa

Detalles Bibliográficos
Autores principales: Falk, Rodney H., Haddad, Mia, Walker, Crystal R., Dorbala, Sharmila, Cuddy, Sarah A.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8543137/
https://www.ncbi.nlm.nih.gov/pubmed/34729530
http://dx.doi.org/10.1016/j.jaccao.2021.08.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8543137/
https://www.ncbi.nlm.nih.gov/pubmed/34729530
http://dx.doi.org/10.1016/j.jaccao.2021.08.007

Ejemplares similares